Gufic Biosciences Limited

Web: gufic.com NSE: GUFICBIO BSE: 509079 SECTOR: Healthcare - Pharmaceuticals & Biotechnology | Add Note | View Notes

440 0(0%)

Near 52W High of 448

Volume

1L as on 23, Jun

Open

431

High

437

Low

428

439

VWAP

368

52 Week High

448

52 Week Low

268

Viand Research Rating

Quality Score

50/100

Growth Score

32/100

Valuation Score

50/100

Momentum Score

45/100

Analyst Recommendations

BUY/SELL

Hold | Buy | Strong Buy

Analyst Price Target

Market Cap (cr)

4,408

No. of Shares

P/E

49.02

P/B

7.82

Face Value

Div. Yield

Book Value (TTM)

CASH

DEBT

EPS (TTM)

ROE

15.95

ROCE

Profit Growth

Listing Date

19-Oct-04

Promoter Holding

72.5%

FII Holding

0.47%

DII Holding

3.67%

Price Chart

Price Performance

1 Week0%

1 Month26%

3 Months32%

6 Months28%

1 Year28%

YTD28%

Moving Average

5 Day SMA362

10 Day SMA363

20 Day SMA358

30 Day SMA335

50 Day SMA320

61 Day SMA314

80 Day SMA0

200 Day SMA0

PIVOT LEVEL

	Standard	Camarilla	Fibonacci	Woodie's
Resistance 3	379	364	373	378
Resistance 2	373	363	369	373
Resistance 1	367	362	366	366
Pivot Point	361	360	361	361
Support 1	355	359	356	354
Support 2	349	358	353	348
Support 3	342	357	349	342

Competitors/Peers

#	Symbol	MCAP	LTP	1W	1M	6M	1Y	P/E	Ind PE	Debt/Eq	NP Qtr Rs.Cr.
1	SUNPHARMA	4,56,655	1899	0%	2%	9%	21%	37	57.7	0.07	11509
2	DIVISLAB	2,43,196	9161	2%	8%	44%	51%	69	57.7	0	2568
3	TORNTPHARM	1,84,303	4846	2%	3%	12%	36%	72	57.7	1.79	2138
4	APOLLOHOSP	1,24,834	8650	1%	1%	12%	10%	58	57.7	0.9	2003
5	ZYDUSLIFE	1,12,897	1132	4%	2%	26%	13%	20	57.7	0.46	5124
6	CIPLA	1,11,346	1385	2%	5%	3%	12%	22	57.7	0.02	3862
7	LAURUSLABS	99,634	1844	3%	3%	75%	114%	0	57.7	0.48	890
8	DRREDDY	96,962	1151	2%	2%	11%	8%	20	57.7	0.2	4158
9	MAXHEALTH	96,646	985	1%	10%	8%	14%	0	57.7	0.32	1442
10	LUPIN	96,620	2113	1%	11%	8%	10%	23	57.7	0.29	5355
Load More

Shareholding Pattern (%)

	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021
Promoters	(0.01) 72.50%	(0.01) 72.50%	(0.01) 72.50%	(0.01) 72.50%	(0.01) 72.51%	(0.01) 72.51%	(0.01) 72.51%	(0.01) 72.51%	(0.01) 72.51%	(0.01) 72.51%	(-2.51) 72.51%	(0.01) 75.00%	(0.01) 75.00%	(0.01) 75.00%	(0.01) 75.00%	(0.01) 75.00%	(-0.51) 75.00%	(0.01) 75.48%	(0.01) 75.48%	(0.01) 75.48%
FIIs	(0.11) 0.47%	(0.01) 0.42%	(0.11) 0.44%	(0.01) 0.33%	(0.01) 0.32%	(0.01) 0.31%	(0.11) 0.30%	(0.01) 0.23%	(0.11) 0.23%	(-0.41) 0.12%	(-0.31) 0.47%	(0.01) 0.72%	(0.01) 0.70%	(0.61) 0.72%	(0.11) 0.16%	(-1.31) 0.06%	(-0.11) 1.38%	(-0.21) 1.51%	(0.21) 1.69%	(0.01) 1.52%
DIIs	(-0.21) 3.67%	(0.11) 3.83%	(0.11) 3.74%	(0.31) 3.66%	(0.01) 3.38%	(0.41) 3.39%	(0.51) 2.99%	(0.11) 2.51%	(0.21) 2.38%	(0.51) 2.20%	(0.11) 1.72%	(0.51) 1.63%	(0.01) 1.16%	(0.01) 1.16%	(0.01) 1.16%	(0.01) 1.16%	(0.01) 1.13%	(-0.11) 1.12%	(-0.91) 1.19%	(0.01) 2.13%
Public	23.36%	23.23%	23.30%	23.51%	23.81%	23.79%	24.20%	24.75%	24.89%	25.17%	25.29%	22.64%	23.12%	23.12%	23.67%	23.76%	22.49%	21.89%	21.64%	20.87%
No. of Shareholders	29,753	29,223	30,362	31,420	31,876	31,844	33,299	32,825	32,250	34,695	34,424	36,557	38,624	38,902	40,562	41,376	40,120	38,144	34,580	35,135

Quarterly Results

	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Sales	261	252	231	237	224	205	208	204	203	195	202	215
Sales Growth % (YoY)	16.6%	22.8%	11.4%	16.1%	10.3%	5.1%	3%	-5%	-	-	-	-
Sales Growth % (QoQ)	3.6%	9.1%	-2.5%	5.8%	9.3%	-1.4%	2%	0.5%	4.1%	-3.5%	-6%	-
Expenses	214	205	198	199	190	179	174	166	167	161	165	176
Operating Profit	47	47	33	38	33	26	34	39	36	34	36	39
OPM %	18	19	14	16	15	13	16	19	18	18	18	18
Other Income	0	-1	1	2	1	0	2	0	1	1	0	0
Interest	9	9	8	10	9	8	5	5	5	4	3	4
Depreciation	8	8	8	8	8	8	5	4	4	4	4	4
Profit before tax	30	29	18	23	17	11	26	29	28	27	30	31
Tax %	26	24	30	26	24	27	26	26	26	26	25	25
Net Profit	22	22	12	17	13	8	19	22	21	20	22	23
Net Profit Growth % (QoQ)	-	83.3%	-29.4%	30.8%	62.5%	-57.9%	-13.6%	4.8%	5%	-9.1%	-4.3%	-
Net Profit Growth % (YoY)	69.2%	175%	-36.8%	-22.7%	-38.1%	-60%	-13.6%	-4.3%	-	-	-	-
TTM Net Profit	73	64	50	57	62	70	82	85	86	65	45	0
EPS in Rs	2.22	2.18	1.24	1.68	1.3	0.77	1.93	2.17	2.08	2	2.22	2.39

Profit and Loss

	Mar 2026	Mar 2025	Mar 2024
Sales	944	820	807
Sales Growth %	15.2%	1.6%	-
Expenses	793	684	657
Operating Profit	151	136	150
OPM %	16	17	19
Other Income	3	4	0
Interest	37	25	17
Depreciation	31	21	17
Profit before tax	87	94	116
Tax %	26	26	26
Net Profit	64	70	86
Net Profit Growth %	-8.6%	-18.6%	-
EPS in Rs	6.4	6.95	8.59
Dividend Payout %	2	1	1

Cash Flows

	Mar 2026	Mar 2025	Mar 2024
Cash from Operating Activity	45	123	-7
Cash from Investing Activity	-31	-71	-102
Cash from Financing Activity	32	-37	82
Net Cash Flow	46	15	-27

Balance Sheet

	Mar 2026	Sep 2025	Mar 2025	Sep 2024	Mar 2024
Equity Capital	10	10	10	10	10
Reserves	655	621	591	564	523
Borrowings	405	369	336	296	333
Other Liabilities	273	271	232	235	227
Total Liabilities	1342	1271	1169	1105	1093
Fixed Assets	491	495	506	149	159
CWIP	22	24	22	363	307
Investments	2	2	2	2	2
Other Assets	827	750	640	590	625
Total Assets	1342	1271	1169	1105	1093

Delivery

Delivery Data: GUFICBIO

#	Date	359 26% 454	Value (Cr)	Q/T 39	Del 38	Del 16
1	4-Sep	445	4	25	51	2
2	3-Sep	439	5	19	44	2
3	2-Sep	439	31	30	30	9
4	1-Sep	421	4	18	47	2
5	31-Aug	416	7	22	39	3
6	28-Aug	406	3	25	50	1
7	27-Aug	412	2	22	55	1
8	26-Aug	408	2	24	62	1
9	25-Aug	414	2	18	55	1
10	24-Aug	418	4	25	53	2
11	21-Aug	432	9	28	45	4
12	20-Aug	414	3	20	52	2
13	19-Aug	422	3	16	51	1
14	18-Aug	421	5	22	46	2
15	17-Aug	418	12	23	37	5
16	14-Aug	422	7	26	58	4
17	13-Aug	430	3	17	51	2
18	12-Aug	425	5	22	48	2
19	11-Aug	431	5	25	57	3
20	10-Aug	433	7	29	61	4
21	7-Aug	421	11	32	55	6
22	6-Aug	404	4	29	56	2
23	5-Aug	394	1	24	60	1
24	4-Aug	397	2	26	62	1
25	3-Aug	390	1	23	55	1
26	31-Jul	390	1	24	67	1
27	30-Jul	384	1	17	48	1
28	29-Jul	382	1	22	61	1
29	28-Jul	388	3	27	48	1
30	27-Jul	382	2	27	55	1
31	24-Jul	379	2	20	60	1
32	23-Jul	377	2	21	53	1
33	22-Jul	386	2	25	55	1
34	21-Jul	397	3	27	64	2
35	20-Jul	394	3	20	47	1
36	17-Jul	382	3	29	46	1
37	16-Jul	388	2	25	49	1
38	15-Jul	397	3	31	51	2
39	14-Jul	399	4	30	46	2
40	13-Jul	400	9	22	41	4
41	10-Jul	392	5	17	52	3
42	9-Jul	387	5	37	60	3
43	8-Jul	380	10	27	37	4
44	7-Jul	380	5	25	36	2
45	6-Jul	375	7	33	55	4
46	3-Jul	390	11	31	39	4
47	2-Jul	386	9	31	46	4
48	1-Jul	394	19	43	28	5
49	30-Jun	407	358	61	9	31
50	29-Jun	386	9	35	42	4

Daily Market Cap

Date	Total Market Cap	Change	Chg %
04-Sep	4,408c	30c	0.68
03-Sep	4,438c	248c	5.91
01-Sep	4,190c	99c	2.43
31-Aug	4,091c	10c	0.23
27-Aug	4,082c	100c	2.39
26-Aug	4,181c	50L	0.01
25-Aug	4,182c	35c	0.85
24-Aug	4,147c	101c	2.37
21-Aug	4,248c	26c	0.61
19-Aug	4,222c	10c	0.23
18-Aug	4,212c	39c	0.91
17-Aug	4,251c	34c	0.81
14-Aug	4,217c	66c	1.53
13-Aug	4,283c	11c	0.25
12-Aug	4,272c	80c	1.84
11-Aug	4,352c	0	0
10-Aug	4,352c	302c	7.45
06-Aug	4,050c	99c	2.50
05-Aug	3,952c	20c	0.50
04-Aug	3,932c	36c	0.93
03-Aug	3,896c	25c	0.64
31-Jul	3,921c	80c	2.08
30-Jul	3,841c	11c	0.29
29-Jul	3,852c	59c	1.50
28-Jul	3,911c	67c	1.73
27-Jul	3,844c	10c	0.25
24-Jul	3,835c	0	0

Stock Checklist

Price is above from 52 week high low average: 95%

Stock is trading above all short term SMAs: NO

Stock is trading above all long term SMAs: YES

Stock is Consistently Improving Long Term: NO

FII purchased in last quarter: YES

Promoters are buying the stock: NO

Mutual Fund Holdings

Held by 19 fund scheme(s) across 6 fund house(s) as of Aug26 · Total value ₹234 Cr · 6 increasing / 7 decreasing · View in MF Pro →

Fund House	Schemes	Weight %	Change	Value (Cr)
ICICI Prudential Mutual Fund	6	0.14%	-0.02%	123.1
Bank of India Mutual Fund	6	0.86%	+0.27%	71.5
SBI Mutual Fund	2	0.36%	-0.10%	39
Bandhan Mutual Fund	2	0.10%	+0.01%	0
Motilal Oswal Mutual Fund	2	0.00%	-	0
ICICI Prudential Asset Management Company Limited	1	0.00%	-0.08%	0

Gufic Biosciences Limited

Price Chart

Price Performance

Moving Average

PIVOT LEVEL

Competitors/Peers

Shareholding Pattern (%)

Quarterly Results

Profit and Loss

Cash Flows

Balance Sheet

Delivery

Daily Market Cap

Stock Checklist

Mutual Fund Holdings

Strategy Builder

Bulk Deals

Events

News

Exchange Filings

Annual Reports

Ratings & Research Reports

Concalls

Announcements